A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers
Summary
- Eligibility
- for people ages 18 years and up (full criteria)
- Location
- at Sacramento, California and other locations
- Dates
- study startestimated completion
Description
Summary
Official Title
Keywords
Eligibility
Locations
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Celgene
- Links
- BMS Clinical Trial Information BMS Clinical Trial Patient Recruiting FDA Safety Alerts and Recalls Sign up for this study
- ID
- NCT03783403
- Phase
- Phase 1 research study
- Study Type
- Interventional
- Participants
- Expecting 230 study participants
- Last Updated